Buscar
Mostrando ítems 1-2 de 2
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...
Artículo
How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey
(Aran Ediciones S.A., 2016)
Introduction: Not all national health centers include special ized units or clinicians devoted to inflammatory bowel disease. The goal of the survey was to gain an insight into the management of this disease within ...